<DOC>
	<DOCNO>NCT02387814</DOCNO>
	<brief_summary>The study involve single dose study drug call abemaciclib take mouth . The purpose study measure much study drug get blood stream long body take get rid give participant mild , moderate , severe liver impairment compare healthy participant . In addition , tolerability study drug evaluate . This study last approximately 3 week participant , include check-in follow-up .</brief_summary>
	<brief_title>A Study Abemaciclib Participants With Varying Degrees Liver Impairment</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Female participant must nonchildbearing potential Have body mass index 18 40 kilogram per square meter ( kg/m^2 ) No history cardiovascular , renal , respiratory , gastrointestinal , endocrine hematological disorder Have know allergy abemaciclib , related compound , component formulation No human immunodeficiency virus ( HIV ) infection antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>